Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 49.94% | 17.37% | 205.50% | 538.49% | 251.02% |
| Gross Profit | -49.94% | -17.37% | -205.50% | -538.49% | -251.02% |
| SG&A Expenses | -16.72% | 0.86% | 18.59% | 217.14% | 111.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.53% | 10.92% | 114.21% | 397.11% | 176.19% |
| Operating Income | -21.53% | -10.92% | -114.21% | -397.11% | -176.19% |
| Income Before Tax | 9.19% | -148.96% | -44.00% | -316.05% | -28.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.19% | -148.96% | -44.00% | -316.05% | -28.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.19% | -148.96% | -44.00% | -316.05% | -28.57% |
| EBIT | -21.53% | -10.92% | -114.21% | -397.11% | -176.19% |
| EBITDA | -21.39% | -10.93% | -114.18% | -397.27% | -177.70% |
| EPS Basic | 15.02% | -148.73% | 0.26% | -54.42% | 52.35% |
| Normalized Basic EPS | 15.04% | -58.46% | 0.41% | -54.35% | -10.83% |
| EPS Diluted | 15.02% | -148.73% | 0.26% | -54.42% | 52.35% |
| Normalized Diluted EPS | 15.04% | -58.46% | 0.41% | -54.35% | -10.83% |
| Average Basic Shares Outstanding | 6.83% | 0.21% | 44.29% | 169.45% | 169.85% |
| Average Diluted Shares Outstanding | 6.83% | 0.21% | 44.29% | 169.45% | 169.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
